Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Sionna Therapeutics, Inc.

SION · Nasdaq · CIK 0002036042 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

22 Form 4 transaction lines observed in the same window
15 sales · 7 option, withholding, award, gift or other lines

Last qualifying purchase2025-06-27 · COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON · $950.4K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Thompson Peter A.Director
▼▼▼▼▼▼
ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCDirector
▼▼▼▼▼▼
Fitzpatrick JenniferCLO and Head of Program Mgmt.
○▼○
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Director; Director,TenPercentOwner
▼
Ridloff ElenaCFO and CBO
○
McKee CharlotteCMO and Head of R&D
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 1 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-06-27 · COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON.

Recent Form 4 activity

0Purchases
108Sales
13Other Form 4 lines
35SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING15 sale line(s) · context only
OTHER7 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
3,797,732
Previous report
3,966,138
Avg daily volume
1,647,766
Days to cover
2.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-06-27COULTER JAMES G; TPG GP A, LLC; WINKELRIED JONPurchase (P)Common Stock60,000USD 15.84USD 950,400SEC filing ↗
2025-02-10COULTER JAMES G; TPG GP A, LLC; WINKELRIED JONPurchase (P)Common Stock1,125,000USD 18.00USD 20,250,000SEC filing ↗
2025-02-10Thompson Peter A.Purchase (P)Common Stock550,000USD 18.00USD 9,900,000SEC filing ↗
2025-02-10ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCPurchase (P)Common Stock550,000USD 18.00USD 9,900,000SEC filing ↗
2025-02-10Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock1,125,000USD 18.00USD 20,250,000SEC filing ↗
2025-02-10Booth BrucePurchase (P)Common Stock60,000USD 18.00USD 1,080,000SEC filing ↗
2025-02-10Atlas Venture Associates Opportunity II, LLC; Atlas Venture Associates Opportunity II, LP; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund II, L.P.Purchase (P)Common Stock60,000USD 18.00USD 1,080,000SEC filing ↗

Form 4 evidence

121 transaction lines in the latest 365-day window; 201 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-17Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Sale (S)Common Stock3,448,811USD 6.33USD 21,835,018SEC filing ↗
2026-09-17Ridloff ElenaAward / grant (A)Common Stock94,537USD 0.00USD 0SEC filing ↗
2026-09-17McKee CharlotteAward / grant (A)Common Stock50,000USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-17Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Sale (S)Common Stock3,448,811USD 6.33USD 21,835,018SEC filing ↗
2026-09-17Ridloff ElenaAward / grant (A)Common Stock94,537USD 0.00USD 0SEC filing ↗
2026-09-17McKee CharlotteAward / grant (A)Common Stock50,000USD 0.00USD 0SEC filing ↗
2026-09-17Fitzpatrick JenniferAward / grant (A)Common Stock56,265USD 0.00USD 0SEC filing ↗
2026-09-17Cloonan MichaelAward / grant (A)Common Stock109,025USD 0.00USD 0SEC filing ↗
2026-07-07Thompson Peter A.Sale (S)Common Stock85,918USD 44.86USD 3,854,281SEC filing ↗
2026-07-07ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock85,918USD 44.86USD 3,854,281SEC filing ↗
2026-07-06Fitzpatrick JenniferSale (S)Common Stock10,250USD 43.60USD 446,900SEC filing ↗
2026-07-06Fitzpatrick JenniferOption exercise / conversion (M)Common Stock10,250USD 6.11USD 62,628SEC filing ↗
2026-06-30Thompson Peter A.Sale (S)Common Stock115,844USD 45.50USD 5,270,902SEC filing ↗
2026-06-30ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock115,844USD 45.50USD 5,270,902SEC filing ↗
2026-05-27Thompson Peter A.Sale (S)Common Stock101USD 44.49USD 4,493SEC filing ↗
2026-05-27ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock101USD 44.49USD 4,493SEC filing ↗
2026-05-11Thompson Peter A.Sale (S)Common Stock184,639USD 46.22USD 8,534,015SEC filing ↗
2026-05-11ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock184,639USD 46.22USD 8,534,015SEC filing ↗
2026-05-08Thompson Peter A.Sale (S)Common Stock59,767USD 44.58USD 2,664,413SEC filing ↗
2026-05-08ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock59,767USD 44.58USD 2,664,413SEC filing ↗
2026-05-07Thompson Peter A.Sale (S)Common Stock48,546USD 44.61USD 2,165,637SEC filing ↗
2026-05-07ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock48,546USD 44.61USD 2,165,637SEC filing ↗
2026-04-18Thompson Peter A.Sale (S)Common Stock2,948USD 44.52USD 131,245SEC filing ↗
2026-04-18ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock2,948USD 44.52USD 131,245SEC filing ↗
2026-04-17Thompson Peter A.Sale (S)Common Stock52,397USD 44.68USD 2,341,098SEC filing ↗
2026-04-17ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock52,397USD 44.68USD 2,341,098SEC filing ↗
2026-04-16Thompson Peter A.Sale (S)Common Stock226,906USD 45.34USD 10,287,918SEC filing ↗
2026-04-16ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock226,906USD 45.34USD 10,287,918SEC filing ↗
2026-04-15Thompson Peter A.Sale (S)Common Stock235,863USD 44.64USD 10,528,924SEC filing ↗
2026-04-15ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock235,863USD 44.64USD 10,528,924SEC filing ↗
2026-04-14Thompson Peter A.Sale (S)Common Stock47,814USD 44.51USD 2,128,201SEC filing ↗
2026-04-14ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLCSale (S)Common Stock47,814USD 44.51USD 2,128,201SEC filing ↗
2026-03-05Fitzpatrick JenniferSale (S)Common Stock10,250USD 33.86USD 347,065SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerSION
CIK0002036042
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history201 transaction lines from 2025-02-10 to 2026-09-17
8 P purchase lines · 160 S sale lines · 33 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.